India is in the grip of a critical nationwide shortage of cisplatin and carboplatin, two essential chemotherapy drugs, caused by a doubling in platinum prices and West Asia shipping disruptions. The NPPA has temporarily raised price caps by 50% to push manufacturers to restart production, making this a key case study on drug pricing regulation, public health preparedness, and supply-chain vulnerability for exams.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›Drugs in Shortage: Cisplatin and Carboplatin
- ›Price Cap Hike: 50% (one-time, review after 6 months)
- ›Target this Data: Cisplatin ceiling price raised from ₹7.26 to ₹10.89 per mL; carboplatin from ₹60.49 to ₹90.74 per mL.
- ›Target this Nodal Body: NPPA (National Pharmaceutical Pricing Authority) invoked special clauses to raise price caps.
- ›Target this Context: Price cap hike was 50%, one-time revision, review after six months, done in public interest.
- ›Target this Issue: Shortage caused by platinum prices more than doubling + West Asia shipping disruptions.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.